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The superoxide (O·−2 )-generating NADPH oxidase of phagocytes consists of a membrane
component, cytochrome b558 (a heterodimer of Nox2 and p22phox ), and four cytosolic
components, p47phox , p67phox , p40phox , and Rac. The catalytic component, responsible
for O·−2 generation, is Nox2. It is activated by the interaction of the dehydrogenase
region (DHR) of Nox2 with the cytosolic components, principally with p67phox . Using a
peptide-protein binding assay, we found that Nox2 peptides containing a 369CysGlyCys371
triad (CGC) bound p67phox with high affinity, dependent upon the establishment of a
disulfide bond between the two cysteines. Serially truncated recombinant Nox2 DHR
proteins bound p67phox only when they comprised the CGC triad. CGC resembles the
catalytic motif (CGHC) of protein disulfide isomerases (PDIs). This led to the hypothesis
that Nox2 establishes disulfide bonds with p67phox via a thiol-dilsulfide exchange reaction
and, thus, functions as a PDI. Evidence for this was provided by the following: (1)
Recombinant Nox2 protein, which contained the CGC triad, exhibited PDI-like disulfide
reductase activity; (2) Truncation of Nox2 C-terminal to the CGC triad or mutating C369
and C371 to R, resulted in loss of PDI activity; (3) Comparison of the sequence of
the DHR of Nox2 with PDI family members revealed three small regions of homology
with PDIA3; (4) Two monoclonal anti-Nox2 antibodies, with epitopes corresponding to
regions of Nox2/PDIA3 homology, reacted with PDIA3 but not with PDIA1; (5) A polyclonal
anti-PDIA3 (but not an anti-PDIA1) antibody reacted with Nox2; (6) p67phox , in which all
cysteines were mutated to serines, lost its ability to bind to a Nox2 peptide containing the
CGC triad and had an impaired capacity to support oxidase activity in vitro. We propose
a model of oxidase assembly in which binding of p67phox to Nox2 via disulfide bonds, by
virtue of the intrinsic PDI activity of Nox2, stabilizes the primary interaction between the
two components.
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INTRODUCTION
Oxygen-derived radicals are the principal mediators responsible
for the killing of pathogenic microorganisms by phagocytes. All
oxygen radicals produced by phagocytes are derived from the
Abbreviations: CGC, 357CysGlyCys371; CGD, chronic granulomatous disease; DE-
GSSG, dieosin glutathione disulfide; DTT, dithiothreitol; DHR, dehydrogenase
region; EC50, half maximal effective concentration; FPLC, fast protein liquid
chromatography; GSG, glutathione disulfide; HMBA, 4-(hydroxymercuri)benzoic
acid; IC50, half maximal inhibitory concentration; LiDS, lithium dodecyl sul-
fate; mBBr, monobromobimane; NEM, N-ethylmaleimide; O·−2 , superoxide;
PAO, phenylarsine oxide; PBS, phosphate buffered saline pH 7.3; PCMB, p-
chloromercuribenzoate; PDI, protein disulfide isomerase; ROS, reactive oxygen
species; Vmax, maximal velocity.
superoxide anion (O·−2 ), generated by the NADPH-derived one-
electron reduction of molecular oxygen. The process is catalyzed
by a membrane-imbedded 91 kDa flavoprotein, known as Nox2,
which is associated with a second protein of 22 kDa (p22phox), to
form the flavocytochrome b558 heterodimer. Nox2 is 570 residues-
long and comprises six transmembrane α-helices linked by three
outside-facing loops and two cytosol-facing loops, and a cytoso-
lic segment, extending from residue 288 to 570. Nox2 contains
all redox stations supporting the flow of electrons from NADPH
to oxygen. These are an NADPH-binding site and non-covalently
bound FAD, present in the cytosolic segment, and two non-
identical hemes present in the third and fifth membrane helices
(reviewed in Quinn and Gauss, 2004).
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In the resting phagocyte, no electron flow occurs along the
redox centers in Nox2. The initiation of the electron flow is medi-
ated by a conformational change in Nox2, resulting from the
interaction with regulatory proteins present in the cytosol. The
regulatory cytosolic components are p47phox, p67phox, p40phox,
and the small GTPase Rac (1 or 2) and they translocate to the
membrane environment of Nox2, to generate the NADPHoxidase
complex (briefly, oxidase), a process known as oxidase assembly
(reviewed in Groemping and Rittinger, 2005). In the intact cell,
p47phox, p67phox, and Rac are all required for the induction of O·−2
production but it is yet unsettled whether direct interaction of all
components with Nox2 is required. There is evidence for p67phox
being the key component responsible for the causation of a con-
formational remodeling of Nox2 (Kreck et al., 1996; Gorzalczany
et al., 2000). Major unsolved issues are the identities of region(s)
in Nox2 and p67phox participating in the interaction among the
two. It has been found that an “activation domain” comprising
residues 199–210 (Han et al., 1998) or a wider region, extending
from residue 190 to 208 (Sumimoto, 2008) in p67phox is essential
for oxidase activation but not for the actual p67phox–Nox2 inter-
action. Experimental evidence related to the latter suggests that
the binding site for Nox2 is located N-terminal to residue 198
(Dang et al., 2002) and, most likely, between residues 187 and 198
or 194 and 198 (Federman Gross et al., 2012).
The cytosolic segment of Nox2 is also known as the dehy-
drogenase region (DHR) by virtue of the fact that it contains
the NADPH- and FAD-binding sites and is homologous to
the prokaryotic protein ferredoxin-NADP+ reductase. The DHR
comprises binding sites for p47phox and Rac but, so far, there is no
solid evidence for the identity of the binding site(s) for p67phox.
We approached this question by applying the “peptide walking”
methodology (Joseph and Pick, 1995; Dahan et al., 2012; Dahan
and Pick, 2012). Overlapping 15-mer peptides, corresponding
to the DHR of Nox2 (residues 288–570) were attached to 96-
well plates and reacted with recombinant 6His-p67phox in the
fluid phase; peptide-bound p67phox was detected by peroxidase-
conjugated anti-polyHis antibody. It was found that p67phox binds
preferentially to two peptides, corresponding to residues 357–371
(termed Nox2 peptide 24) and 369–383 (termed Nox2 peptide
28) (Dahan and Pick, manuscript in preparation). The peptides
share a 369CysGlyCys371 (CGC) triad, located at the C-terminus
of peptide 24 and the N-terminus of peptide 28. The CGC triad
is present in the DHR of Nox2 of all species, down to amphib-
ians, and is absent in Nox1, 3, 4, and 5 (Kawahara et al., 2007).
Peptides derived from Nox4, corresponding to Nox2 peptides 24
and 28 by sequence alignment but lacking the CGC triad, did not
bind p67phox. It is of interest that Nox4 generates oxygen radicals
constitutively, without a requirement for cytosolic activators, such
as p67phox (Bedard and Krause, 2007).
Replacing C369 or C371 with Arg or Ser abolished binding
of p67phox to peptides 24 and 28. A 369Cys to Arg mutation in
Nox2 causes chronic granulomatous disease (CGD) of the X91+
form, with normal expression of Nox2 but impaired production
of O·−2 , impaired translocation of cytosolic components, and low
FAD binding (Leusen et al., 2000; Debeurme et al., 2010).
We next found that the introduction of an intramolecu-
lar disulfide bond between C369 and C371 in Nox2 peptides
24 and 28 resulted in a marked increase in the binding of
p67phox. Reduction of the disulfide bond and alkylation of the
reduced thiols totally abolished binding of p67phox (Fradin et al.,
2011, 2012; Pick, 2012; Fradin and Pick, manuscript in prepa-
ration). An important observation was that enhanced binding
of p67phox was evident only when the disulfide bond was estab-
lished between two non-adjacent cysteines and between cysteines
present in the same peptide; when the CGC triad was replaced
by CCG and a disulfide bond established between the adjacent
cysteines or the disulfide bond linked C369 or C371 on two
peptides, forming a dimer, no enhanced binding of p67phox was
found.
These observations are to be related to a large body of early
work by several groups showing that thiol alkylating agents inter-
fere with oxidase activation in intact phagocytes and in in vitro
systems. Thus, N-ethylmaleimide (NEM) inhibited oxidase acti-
vation in intact phagocytes, if added before activation (Cohen and
Chovaniec, 1978; Yamashita et al., 1984) and in vitro (Shpungin
et al., 1989) and was shown to act on a membrane compo-
nent (Shpungin et al., 1989). Similar results were obtained with
4-(hydroxymercuri)benzoic acid [HMBA, known in the past as
p-chloromercuribenzoate (PCMB)]. A solubilized membrane-
associated fraction, prepared from stimulated neutrophils, was
inactivated by HMBA (Bellavite et al., 1983; Gabig and Lefker,
1984) and macrophage membrane liposomes treated with HMBA
were inactive in a cell-free oxidase activation system (Pick et al.,
1987). Less defined evidence exists for cysteines being the tar-
get for the oxidase inhibitors apocynin, VAS2870, and ebse-
len, and the specific components affected were not rigorously
identified.
More recent testimony for the involvement of Nox2-localized
cysteines in oxidase function was provided by the discovery of the
marked inhibitory effect of phenylarsine oxide (PAO), an agent
which reacts with vicinal dithiols to form a disulfide-like com-
plex (van Iwaarden et al., 1992). PAOwas found to inhibit oxidase
activation in neutrophils and in vitro, when preincubated with
the membrane fraction, a reaction that was reversed by reduc-
ing agents (Le Cabec and Maridonneau-Parini, 1995). PAO was
proposed to act on the pair of cysteines 369 and 371 in Nox2
(Doussiere et al., 1998). More support for the role of vicinal cys-
teines in Nox2 in oxidase activation was offered by the inhibitory
effect of the fungal toxin gliotoxin (Waring and Beaver, 1996),
which contains a bridged disulfide ring capable of forming mixed
disulfides with thiol-containing proteins. Gliotoxin was reported
to inhibit oxidase activation in neutrophils (Tsunawaki et al.,
2004) and in vitro, with the vicinal cysteines 369 and 371 in Nox2,
considered as likely targets (Nishida et al., 2005). Gliotoxin did
not affect Nox4 (Serrander et al., 2007), in good agreement with
the facts that Nox4 does not contain the CGC triad and does
not require cytosolic assistance for generation of reactive oxygen
species (ROS).
On considering our results on the binding of p67phox–Nox2
peptides containing the CGC triad, in the disulfide form, and
the accumulated evidence in support of a role for these cys-
teines in oxidase assembly, we reasoned that, at a certain stage
in the process of oxidase assembly, the intramolecular disulfide
bond in Nox2 might be converted to an intermolecular disulfide
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bond between Nox2 and cysteines in p67phox by a thiol—disulfide
exchange reaction. It is likely that the primary interaction between
the Nox2DHR and p67phox is based on specific binding sites in the
two partners and does not involve disulfide bonds. The establish-
ment of disulfide bonds between cysteines in the Nox2 CGC triad
and cysteines in p67phox is a secondary event with a stabilizing
role.
It is our hypothesis that Nox2 serves as an endogenous protein
disulfide isomerase (PDI), when the cysteines in the CGC triad are
in the disulfide form. PDIs are multi-domain proteins belonging
to the thioredoxin superfamily (reviewed in Collet and Messens,
2010) and to the PDI gene family, which comprises 21 mem-
bers, varying in size, domain composition and tissue expression
(reviewed in Ellgaard and Ruddock, 2005; Appenzeller-Herzog
and Ellgaard, 2008; Galligan and Petersen, 2012; Ali Khan and
Mutus, 2014). PDIs can catalyze thiol—disulfide oxidation and
reduction and disulfide rearrangement (isomerization) and also
function as chaperones. PDIs contain two thioredoxin-like cat-
alytic domains, with a characteristic CXXC active site motif. This
is CGHC, in most PDIs, as opposed to the CGPC sequence,
typical of thioredoxin.
The proposal that Nox2 acts as a PDI is backed by the follow-
ing body of evidence: (a) The CGC triad closely mimics the two
CGHC catalytic motifs of PDI; thus CGC has a disulfide reduc-
tion potential (E◦′) of −167mV, which is very close to that of
the CGHC motif of PDI (−180mV) (Woycechowsky and Raines,
2003); (b) The disulfide bond in CGC is relatively unstable with
high loop opening (ko) and closing (kc) constants, a property
favorable to PDI activity (Zhang and Snyder, 1989; Kersteen and
Raines, 2003); (c) Small peptides CGC and RKCGC, in the disul-
fide form, can mimic the actions of PDI protein (Kersteen and
Raines, 2003; Wang et al., 2011), and (d) The CGC triad resem-
bles similar motifs appearing in a large family of eukaryotic and
prokaryotic enzymes known as thiol-disulfide oxidoreductases,
which contain one or more di-cysteine motifs and, sometimes,
a flavin cofactor (Sevier and Kaiser, 2002).
In the present work we present the experimental evidence in
support of the hypothesis that the DHR of Nox2 functions as
a PDI, leading to establishment of disulfide bonds with p67phox
and assuring the stabilization of the NADPH oxidase com-
plex. This conclusion is based on the use of a wide range of
methodologies, comprising the generation of recombinant DHR
of Nox2 and p67phox and mutants of these, protein - protein
and peptide—protein binding assays, an enzymatic PDI reductase




Synthetic peptides corresponding to selected sequence segments
of Nox2 were made by two companies: Mimotopes (Clayton,
Victoria, Australia), and Bachem (Bubendorf, Switzerland).
Peptides were 15-residues-long, with a biotin tag at the N-
terminus (attached by a Ser-Gly-Ser-Gly spacer) and a C-terminal
amide. Peptides were of a purity of at least 70%, documented
by reversed phase chromatography, and the size, confirmed by
MALDI-mass spectroscopy. Peptides were dissolved in a mixture
of 75 parts 1-methyl-2-pyrrolidone and 25 parts water (v/v), to a
concentration of 1.5mM, to serve as stock solutions for further
dilution, and kept frozen at −75◦C in small aliquots. Working
solutions were freshly prepared on the day of performing the
experiments.
CHEMICALS
Common laboratory chemicals, at the highest purity available,
were purchased from Merck KGaA (Darmstadt, Germany), or
Sigma-Aldrich (St. Louis, MO, USA). The following potential PDI
inhibitors were used: phenylarsine oxide (Sigma-Aldrich); baci-
tracin (mixture of 9 bacitracins, mainly type A; Sigma-Aldrich);
gliotoxin (from Gliocladium fimbriatum, Fermentek, Jerusalem,
Israel); PDI inhibitor 16F16 (Sigma-Aldrich); ribonuclease A,
with scrambled disulfide bonds from bovine pancreas (Sigma-
Aldrich), rutin hydrate (Sigma-Aldrich), and PDI inhibitor
III, PACMA 31 (Merck). Dieosin glutathione disulfide (DE-
GGSG), used in the PDI reductase assay, was a kind gift of Dr.
Bulent Mutus (University of Windsor, Ontario, Canada). Nickel
Sepharose 6 Fast Flow was obtained from GE Healthcare Bio-
Sciences AB, Uppsala, Sweden. Monobromobimane Fluoropure
grade (mBBr) was obtained from Molecular Probes, Life
Technologies, Thermo Fisher Scientific, Waltham, MA, USA.
RECOMBINANT PDI
Recombinant PDI A1 (human; >95% pure; Cat. No. enz-262),
made in E. coli, comprising a 12-His tag at the N-terminus, and
recombinant PDI A3 (human; >95% pure; Cat. No. enz-474),
made in E. coli, comprising residues 25–505 and a 37-His tag at
the N-terminus, were obtained from ProSpec-Tany TechnoGene
(Ness Ziona, Israel).
RECOMBINANT CYTOSOLIC NADPH OXIDASE COMPONENTS
Recombinant p67phox, p47phox, and Rac1 (Q61L mutant), with
an N-terminal 6His tag, were expressed in E. coli and purified
on Nickel Sepharose, as described before (Mizrahi et al., 2010).
Recombinant non-prenylated Rac1 was prenylated in vitro by
recombinant mammalian geranylgeranyltransferase type I (a gift
of Dr. Carolyn Weinbaum, Duke University), as described before
(Gorzalczany et al., 2002).
GENERATION OF RECOMBINANT p67phox WITH 4 Cys TO Ser
MUTATIONS
We generated recombinant p67phox(1–212), in which cysteines 40,
45, 121, and 165 were mutated to serine. To construct a 6His-
tagged protein in which the four cysteines were concurrently
changed to serine, we used a synthetic gene encoding p67phox
amino acids 1–212, comprising the four mutations in plasmid
pIDTSmart AMP (Integrated DNA Technologies, Coralville, IA,
USA). This was subcloned into the BamHI-EcoRI restriction
sites of plasmid pET-30a-His6, as described for wild-type p67phox
(Mizrahi et al., 2010). The mutant protein was expressed in E. coli
and purified on Nickel Sepharose, essentially as described for
wild-type p67phox. The only deviation from the procedure applied
to wild-type p67phox was the supplementation of all buffers used
for washing the Nickel Sepharose beads, and for binding and elut-
ing the protein, with 0.2% (v/v) Triton X-100 (Sigma-Aldrich),
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with the purpose of preventing hydrophobic interaction with
Nickel Sepharose. Such interaction was more pronounced with
the mutant protein.
PHAGOCYTE MEMBRANES
Phagocyte membranes were prepared from guinea pig peritoneal
macrophages elicited by the injection of mineral oil (Bromberg
and Pick, 1984). The membranes were solubilized in 40mM
n-octyl ß-D-glucopyranoside and reconstituted into liposomes
by dialysis against detergent-free buffer as described previously
(Shpungin et al., 1989). The specific cytochrome b558 heme
content of membrane vesicles was measured by the difference
spectrum of sodium dithionite-reduced minus oxidized samples
(Pick et al., 1987).
PREPARATION OF NusA-Nox2 FUSION PROTEINS
Recombinant fusion proteins linking parts of the DHR of
human Nox2 (residues 288–570) with the E. coli protein NusA
were constructed in order to obtain soluble Nox2 preparations.
Recombinant NusA was also made, to serve as a negative con-
trol. The method was based on the ability of NusA to markedly
improve the solubility of the fusion partner while conserving
biological activity (Davis et al., 1999). Details of the construc-
tion of the fusion proteins are described under “Construction of
NusA-Nox2 fusion proteins” in Supplementary Material. Fusion
proteins were constructed to contain C-terminal to NusA the fol-
lowing Nox2 truncations: residues 328–570, 357–570, 372–570,
387–570, 408–570, 444–570, and 462–570. In addition, the fusion
protein NusA-Nox2(357–570) was subjected to mutagenesis, in
which Cys369 and Cys371 were mutated to Arg. The mutants were
constructed using the “QuickChange Site-Directed Mutagenesis
Kit” (Agilent Technologies, Santa Clara, CA, USA). Plasmid pET-
43a-Nox2(357–570) was used as a template. The integrity of the
mutant genes was confirmed by DNA sequencing. The fusion
proteins and NusA were expressed in E. coli and purified on
Nickel Sepharose, as described for the recombinant cytosolic
NADPH oxidase components (Mizrahi et al., 2010). The NusA-
Nox2 fusion proteins and NusA were further purified by fast
protein liquid chromatography (FPLC) gel filtration on a HiLoad
16/60 Superdex 200 prep grade column (GE Healthcare Bio-
Sciences AB), as described before (Mizrahi et al., 2010). This
procedure separated a polymeric fraction from a homodimer
fraction (197 kDa in size for NusA-Nox2(357–570), and 145 kDa,
for NusA). The purified homodimers were used in enzymatic and
immunologic assays.
DETERMINATION OF PROTEIN CONCENTRATION AND PURITY
The protein concentration of the recombinant proteins was mea-
sured by the method of Bradford (1976), modified for use with
96-wells microplates, using Bio-Rad protein assay dye reagent
concentrate (Bio-Rad Laboratories, Hercules, CA, USA) and
bovine γ-globulin as a standard. The level of purity of the recom-
binant proteins was assessed by SDS-PAGE analysis.
SDS-PAGE
SDS-PAGE was performed in a XCell SureLock Mini-Cell, using
precast 12%, 1-mm thick, 10 well, NuPAGE Bis-Tris gels, and
NuPAGE MOPS SDS running buffer. Run was at a constant
voltage of 200V for 50min. All items were obtained from
Novex, Life Technologies, Carlsbad, CA, USA, and the manufac-
turer’s instructions were followed. Molecular weight standards
(Precision Plus, All Blue, range 250–10 kDa, prestained) were
purchased from Bio-Rad. The gels were stained by Instant Blue
(Expedeon, Harston, UK).
ANTIBODIES
The following anti-human Nox2 antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA): anti-Nox2
54.1 (mouse monoclonal, recognizing epitope 381–390 in the
cytosolic segment of Nox2; Burritt et al., 1995; Baniulis et al.,
2005); anti-Nox2 NL7 (mouse monoclonal, recognizing epi-
tope 498–506 in the cytosolic segment of Nox2; Burritt et al.,
2003), and anti-Nox2 C-15 (goat polyclonal raised against a pep-
tide in the C-terminal region of Nox2; sequence is unknown).
The following anti-human PDIA3 antibodies were used in
this study: anti-PDIA3 H-220 (rabbit polyclonal, raised against
residues 108–207; Santa Cruz); anti-PDIA3 HPA003230 (rab-
bit polyclonal, raised against residues 101–218; Sigma-Aldrich,
Prestige Antibodies); anti-PDIA3 NBP-84797 (rabbit polyclonal,
raised against residues 246–377; Novus Biologicals, Littleton,
CO, USA), and anti-PDIA3 ABE1032 (rabbit polyclonal, raised
against whole human recombinant PDIA3; Merck). Anti-human
PDA1 antibody H-160 (rabbit polyclonal, raised against residues
211–370) was obtained from Santa Cruz. Anti-polyhistidine anti-
body A7058 (mouse monoclonal, peroxidase conjugate) was
obtained from Sigma-Aldrich. Anti-Nus-Tag antibody (mouse
monoclonal, with high affinity for NusA protein for detection
of fusion proteins containing the Nus-Tag expressed with the
pET-41.1 vector) was obtained from Novagen, EMD Chemicals,
Merck. Second anti-mouse IgG (A3562), anti-rabbit IgG (A3687),
and anti-goat IgG (A7650) antibodies, all conjugated with alka-
line phosphatase, were obtained from Sigma-Aldrich. Rabbit
anti-mouse IgG, conjugated with peroxidase (Cat. No. 315-035-
003) was obtained from Jackson ImmunoResearch, West Grove,
PA, USA.
IMMUNOBLOTTING
Immunoblotting was performed essentially as described before
(Knoller et al., 1991), with a number of modifications. The block-
ing buffer consisted of NaCl (136mM), Tris-HCl (25mM), and
KCl (2.68mM), pH 7.5, supplemented 3 g% of bovine serum
albumin (A4053, 96%, Sigma-Aldrich) and 0.1% (v/v) Triton
X-100. A Pierce G2 Fast Blotter semi-dry transfer apparatus and
1-Step Transfer Buffer (Prod. No. 84731) were used, following the
manufacturer’s instructions (Thermo Fisher Scientific). Second
antibodies were alkaline phosphatase conjugates and bands were
detected by direct color development, using SIGMAFAST BCIP-
NBT reagent (B5655, Sigma-Aldrich).
PROTEIN—PROTEIN BINDING ASSAY
This assay was used to assess the binding of NusA-Nox2 fusion
proteins to p67phox. p67phox was diluted in phosphate buffered
saline (PBS) (consisting of 137mM NaCl, 2.7mM KCl, 4.3mM
Na2PO4, and 1.4mM KH2PO4, pH 7.3) to a concentration of
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0.5μM. 200μl amounts were added to the wells of a 96-well plate
(Immulon 4 HBX ultra-high binding flat bottom polystyrene,
Cat. No. 3855, Thermo Labsystems, Helsinki, Finland). p67phox
was allowed to attach to the wells for 16–18 h at 4◦C, the well con-
tents being mixed on an orbital shaker. Unattached protein was
removed by repeated washing with PBS supplemented with 0.1%
v/v Tween 20 (Sigma-Aldrich), using aWellwash Versa microplate
washer (Thermo Fisher Scientific). Next, the surface-attached
p67phox was exposed to 200μl/well of NusA-Nox2 or NusA,
diluted to a concentration of 0.5μM in PBS supplemented with
0.1% Tween 20 and 1% w/v casein, sodium salt (Sigma-Aldrich),
for 1 h at room temperature, the well contents being mixed on an
orbital shaker. After repeated washing, we added 200μl/well anti-
NusA antibody, diluted 1/2500 in in PBS supplemented with 0.1%
Tween 20 and 1% w/v casein, for 1 h at room temperature with
shaking. This was followed, after further washing, by 200μl/well
of peroxidase conjugated anti-mouse IgG, diluted 1/2500 in PBS
supplemented with 0.1% Tween 20 and 1% w/v casein, and
incubation for 1 h at room temperature, with shaking. After
washing off the second antibody, bound peroxidase was quanti-
fied by adding 200μl/well of tetramethyl benzidine + substrate
chromogen reagent (DakoCytomation, Glostrup, Denmark) and
measuring the increase in absorbance at 650 nm over time, for
10min (Dahan and Pick, manuscript in preparation). Absorbance
was measured in a Spectramax 340 microplate reader, in the
kinetic mode (Molecular Devices, Sunnyvale, CA, USA) fitted
with SoftMax Pro 5.2 software. Results were expressed as mAbs
at 650 nm per min.
PEPTIDE—PROTEIN BINDING ASSAY
This assay was used to assess the binding of p67phox, in solu-
tion, to surface-attached synthetic Nox2 peptides. The procedure
is a modified version of that described before (Morozov et al.,
1998; Dahan et al., 2002). A brief description of the procedure
is presented here. Synthetic Nox2 peptides, with a biotin tag at
either the N- or C-terminus, were diluted to a concentration
of 1μM in PBS supplemented with 1% casein. 200μl/well vol-
umes were added to streptavidin-coated 96 well plates (BioBind
Assembly, streptavidin-coated, Cat. No. 95029263, Thermo Fisher
Scientific) and the plates incubated for 1 h at room tempera-
ture, the well contents being mixed on an orbital shaker. After
removing the unattached peptide by repeated washing with PBS
supplemented with 1% v/v Tween 20, the wells were filled with
200μl volumes of p67phox at a concentration of 1.5μM in PBS,
supplemented with 1% casein, and the plates kept for 16–18 h
at at 4◦C with shaking on an orbital shaker. After removal of
unattached p67phox by repeated washing, 200μl/well of a 1/3000
dilution of peroxidase-conjugated anti-polyhistidine antibody in
PBS, supplemented with 0.1% Tween 20 and 1% w/v casein, were
added and the plate incubated for 1 h at room temperature, with
shaking. Bound peroxidase was quantified as described for the
protein—protein binding assay.
MEASURING PDI REDUCTASE ACTIVITY
The various methods of assaying PDI activity were recently
reviewed (Watanabe et al., 2014). Preliminary experiments were
performed using the turbidimetric assay based on the reduction
of disulfides in oxidized insulin (Holmgren, 1979; Martinez-
Galisteo et al., 1993) but this was abandoned when it was found
not to be sufficiently sensitive for assessing the PDI activity of
NusA-Nox2 fusion proteins. Consequently, we opted for a highly
sensitive fluorescent method of measuring the disulfide reductase
activity of PDI (Raturi and Mutus, 2007). The principle of this
method is the use of DE-GSSG, in which two eosin molecules,
covalently attached to glutathione disulfide (GSSG), exhibit flu-
orescent self quenching due to their proximity. On addition of
PDI, in the presence of a minimal concentration of dithiothreitol
(DTT), the disulfide bond in GSSG is reduced and the sepa-
ration of the eosin molecules results in a ∼70-fold increase in
fluorescence. We first tested the feasibility of using this assay by
measuring the activity of recombinant PDIA1 and PDIA3, fol-
lowing the assay conditions of Raturi and Mutus (2007). The
assay mixture consisted of various concentrations of PDI in 1ml
volumes of 0.1M potassium phosphate buffer, pH 7.0 supple-
mented with 2mM EDTA, 150 nM DE-GSSG, and 5μM DTT.
Control mixtures consisted of PDI, in the absence of DTT, and
of DTT, in the absence of PDI. The kinetics of fluorescence
was initially measured in an FP-750 spectrofluorometer (JASCO
Corporation, Tokyo, Japan), with excitation at 519 nm and emis-
sion, at 539 nm, in a stirred cuvette, for 15–30min in the time
course mode. The necessity to perform numerous measurements
simultaneously and repeated measurements on the same sam-
ple led us to switch to the use of 96 well plates and a Gemini
XPS microplate spectrofluorometer (Molecular Devices) fitted
with SoftMax Pro 5.2 software. The assays were performed in
Microfluor 1 Black flat bottom low background plates (Part
7605, Thermo Labsystems, Franklin, MA, USA). To each well
were added, in a 200μl volume, an assay mixture consisting
of various concentrations of PDI in 0.1M potassium phos-
phate buffer, pH 7.0 supplemented with 2mM EDTA, 0.8μM
DE-GSSG, and 12.5μM DTT. The kinetics of fluorescence was
measured, with excitation at 519 nm and emission, at 545 nm,
for 30min, at 24◦C, with six readings on the same well and
mixing of the wells between readings. Results were expressed
as Vmax (milli relative fluorescence units per min), following
selection of the linear segment of the increase in fluorescence
curve.
ASCERTAINING THE ABSENCE OF CYSTEINES IN THE p67phox
MUTANT PROTEIN
The conversion of cysteines to serines in the p67phox mutant
was confirmed at the stage of constructing the mutant by DNA
sequencing. We, nevertheless, ascertained the presence of cys-
teines in wild-type p67phox(1–212) and their absence in the
mutant, by the binding or absence of binding of the thiol reagent
monobromobimane (mBBR). mBBR is non-fluorescent when
free and becomes fluorescent upon binding to thiol groups in
proteins (Kosower and Kosower, 1995).
CELL-FREE NADPH OXIDASE ACTIVATION ASSAYS
Two variations of the cell-free NADPH oxidase assay were
used. The canonical assay, known as the amphiphile- and
p47phox-dependent assay, involves the participation of phago-
cyte membranes (as a source of cytochrome b558), p47phox,
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p67phox, Rac1 in the GTP-bound form, and an activating anionic
amphiphile, such as arachidonate or lithium dodecyl sulfate
(LiDS) (Bromberg and Pick, 1984, 1985). The second varia-
tion, known as the amphiphile- and p47phox-independent assay,
involves the participation of phagocyte membranes, p67phox, and
Rac1 and does not require an amphiphilic activator (Gorzalczany
et al., 2000). Detailed descriptions of both methodologies have
been published (Pick, 2014). In the vast majority of assays,
NADPH oxidase activity was quantified by the production
of superoxide (O·−2 ), measured by the reduction of oxidized
cytochrome c. In some cases, when compounds, such as certain
PDI inhibitors, interfered with cytochrome c reduction, we used
NADPH consumption, as an alternative (Sha’ag, 1989). Results
were expressed as turnover values (mol O·−2 /s/mol cytochrome
b558 heme).
EFFECT OF PDI INHIBITORS ON CELL-FREE NADPH OXIDASE
AVTIVATION
A number of agents described as PDI inhibitors were tested
for an effect on cell-free NADPH oxidase activation. Based on
the hypothesis that the target of such inhibitors is located in
the phagocyte membrane and, specifically, in Nox2, the cell-
free assays were designed in a manner to allow pre-incubation
of the inhibitors with the phagocyte membranes for 5min,
at room temperature. This was followed by the addition of
p47phox, p67phox, Rac1 and LiDS (in the canonical assay), or
p67phox and prenylated Rac1 (in the amphiphile- and p47phox-
independent assay) and further incubation for 90 s or 5min,
respectively.
GRAPH PLOTTING
Plotting of graphs and kinetic analyses were executed by using
GraphPad Prism Version 6.05 (GraphPad Software, San Diego,
CA, USA).
RESULTS
EXCHANGING THE CGC TRIAD IN Nox2 PEPTIDE 24 WITH CGHC OR
CGPC CONSERVES BUT DOES NOT AUGMENT THE ENHANCEMENT OF
p67phox BINDING
We found that two synthetic 15-mer peptides, derived from the
DHR of Nox2, which share a CGC triad at either the C- or
N-terminus (designated peptides 24 and 28, respectively) bind
full-length (1–526) and truncated (1–212) p67phox with low affin-
ity and the introduction of an intramolecular disulfide bond
linking cysteines 369 and 371 leads to a marked increase in the
binding of p67phox. Based on the resemblance of the CXC motif
with the CXXC motif characteristic of the catalytic motifs of
PDI and thioredoxin, we synthesized analogs of Nox2 peptide
24 (IVGDWTEGLFNACGC) in which the CGC sequence was
replaced by either CGHC (the catalytic motif of PDI) or CGPC
(the catalytic motif of thioredoxin). Both peptide analogs were
prepared in the reduced and the disulfide forms and examined for
the ability to bind p67phox, in comparison with the unmodified
peptide 24. As apparent in Figure 1, the introduction of a disul-
fide bond in both modified peptides (CGHC and CGPC) caused
a significant increase in p67phox binding but the levels of bind-
ing were inferior to those measured with the disulfide form of the
FIGURE 1 | The enhanced binding of p67phox to Nox2 peptides with an
intramolecular disulfide bond is maximal when the cysteines are
separated by a single glycine. The binding of p67phox (1–212), in solution,
to surface-attached native and modified Nox2 peptide 24 (357–371), with an
N-terminal biotin tag, was measured. The native peptide comprises the
369CysGlyCys371 triad at the C-terminus, in the dithiol form (labeled 24N
CGC), and a disulfide form was synthesized, with an intramolecular
disulfide bond between cysteines C369 and C371 (labeled 24N CGC S-S).
Two more peptides were synthesized in which the CGC triad was replaced
with CysGlyHisCys (labeled 24N CGHC) or CysGlyProCys (labeled 24N
CGPC), to mimic the catalytic sites of PDI and thioredoxin, respectively.
These two peptides were also synthesized in the dithiol form and with an
intramolecular disulfide bond between cysteines 369 and 372. The
methodology is described in the Materials and Methods Section. Results
represent means ± SEM of three experiments.
original peptide 24. Identical results were obtained when peptide
24 and the modified peptides, all in the reduced form, were sub-
jected to oxidation by 1mM H2O2, a procedure found to lead to
the formation of intramolecular disulfide bonds between vicinal
cysteines. These results are in good agreement with the findings
of Woycechowsky and Raines (2003), showing that a CGC tripep-
tide, with an amidated C-terminus, is a good functional mimic
of PDI.
ALKYLATION OR OXIDATION OF THIOLS IN p67phox INTERFERES WITH
BINDING TO Nox2 PEPTIDES CONTAINING THE CGC TRIAD
The findings that binding of p67phox to Nox2 peptides contain-
ing the CGC triad was abolished when either C369 or C371
were exchanged to arginine or serine, and that Nox4 peptides,
corresponding by alignment to Nox2 peptides 24 and 28, did
not bind p67phox, as well as the clinical correlate showing that
a C369 to R mutation in Nox2 causes the X91+ form of CGD,
with impaired translocation of cytosolic components, represent
strong indicators for disulfide bonds being established between
Nox2 and p67phox cysteines. To test this hypothesis directly, we
treated p67phox with the thiol alkylating agent NEM or the thiol
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oxidants diamide and H2O2 and measured binding to peptide
24 in the native and disulfide form. We found that pretreatment
of p67phox with either NEM (Figure 2A) or diamide (Figure 2B)
totally abolished binding to Nox2 peptide 24 in the disulfide form.
Both reagents also suppressed the low affinity binding to the
native form of the peptide. These findings support the hypoth-
esis that some form of thiol—disulfide exchange is involved
in the binding of p67phox to Nox2. Treatment of p67phox with
H2O2 also markedly reduced the binding of p67phox to peptide
24 in the disulfide form but a surprisingly high concentra-
tion oh H2O2(10mM) was required for the effect to take place
(Figure 2C).
CONSTRUCTION OF RECOMBINANT FUSION PROTEINS COMPRISING
SEGMENTS OF THE DHR OF Nox2
We have generated a number of recombinant fusion proteins con-
sisting of the E. coli protein NusA and parts of the DHR of Nox2,
starting at residues 328, 357, 372, 387, 408, 444, and 462, all end-
ing at the C-terminus of Nox2 (residue 570) (Figure 3). As a
control protein, we expressed NusA not fused to Nox2. Most work
was performed with the fusion protein NusA-Nox2(357–570),
which was the longest form which was predominantly soluble.
Since all fusion proteins and NusA, too, consisted of a mixture
of polymers and homodimers, we purified the proteins by gel fil-
tration and used the homodimer fraction in all experiments. As
seen in Figure 3, fusion protein NusA-Nox2(357–570) comprised
residues 357–383, which correspond to the overlapping peptides
24 and 28, and, thus, contained the CGC triad. It also contained
all parts of the NADPH-binding site and part of the FAD-ribityl
binding site. The five shorter truncated proteins lacked the CGC
triad.
For the immunologic characterization of the fusion proteins,
we used two mouse monoclonal anti-human Nox2 antibodies.
Antibody 54.1 reacted with Nox2 epitope 381-390 and anti-
body NL7 reacted with epitope 498–506. The locations of the
two epitopes on the serially truncated Nox2 proteins are indi-
cated in Figure 3. All truncated Nox2 proteins were subjected to
immunoblot analysis. As apparent in Figure 4A, antibody 54.1
reacted with proteins NusA-Nox2(357–570) and (372–570) and
weakly, with (387–570), in perfect correlation with the presence
and absence of the relevant epitopes. Antibody NL7 reacted, as
expected, with all the truncated proteins, in accordance with the
presence of the relevant epitope on all truncations (Figure 4B).
Thus, the structure of all NusA-Nox2 fusion proteins to be used in
the present work, predicted by DNA sequencing, was confirmed
by their immunologic characteristics.
FIGURE 2 | Treatment of p67phox with N-ethylmaleimide (NEM),
diamide, or H2O2reverses the enhanced binding to Nox2 peptides
containing an intramolecular disulfide bond. p67phox (1–526) (1.5μM)
was incubated with NEM (0.1mM) (A) or diamide (5mM) (B), for 1 h at
room temperature. p67phox (1–212) (1.5μM) was exposed to H2O2 (0.1, 1,
or 10mM) for 2 h at 4◦C (C). Control preparations were supplemented
with equal volumes of PBS for the same time interval. The binding of
treated and untreated p67phox , in solution, to surface-attached Nox2
peptide 24 (357–371), with an N-terminal biotin tag, was measured.
Binding to peptide 24 in the dithiol form (labeled 24N) and/or only (in the
case of exposure to H2O2) to the peptide with an intramolecular
disulfide bond between cysteines C369 and C371 (labeled 24N S-S) was
assessed. Results shown in all panels represent means ± SEM of three
experiments.
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FIGURE 3 | Recombinant NusA-Nox2 proteins used in the present
work. A number of NusA-Nox2 fusion proteins, consisting of NusA and
segments of the dehydrogenase region of Nox2, were constructed (see
Materials and Methods and Supplementary Material). The figure shows a
schematic representation of the serial N-terminal truncations of the Nox2
part of the fusion proteins. It also illustrates the location of peptides 24
(357–371) and 28 (369–383); the position of the FAD- and NADPH-binding
sites, and the epitopes of the two monoclonal anti-Nox2 antibodies used
in the present work. The truncation most used (357–570) is marked by a
red-colored ellipse.
BINDING OF NusA-Nox2 FUSION PROTEINS TO p67phox IS
DEPENDENT ON THE PRESENCE OF THE CGC TRIAD IN Nox2
We used a protein—protein binding assay to measure the abil-
ity of the various NusA-Nox2 truncations to bind to p67phox.
NusA not fused to Nox2 segments was used as a negative con-
trol. In these experiments, the homodimeric forms of NusA-Nox2
and NusA, derived by purification by gel filtration, were used. As
seen in Figures 5A,B, only NusA-Nox2(328–570) and (357–570)
exhibited significant binding to p67phox. The shorter trunca-
tions bound to p67phox to an extent similar to that of unfused
NusA. These results demonstrate the need for the presence of
the CGC triad in Nox2 for binding to p67phox since only NusA-
Nox2(328–570) and (357–570) comprise the CGC triad (see
Figure 3). Binding to p67phox(1–212) exceeded that to p67phox(1–
526), in accordance with data indicating that a conformational
change in p67phox(1–526) is required for optimal binding (Dang
et al., 2002; Federman Gross et al., 2012).
THE NusA-Nox2 FUSION PROTEIN EXHIBITS PDI REDUCTASE ACTIVITY
The availability of a soluble and well-characterized fusion pro-
tein comprising a major part of the DHR of Nox2 offered the
opportunity to test it for the presence of enzymatic PDI activity.
We first used the insulin reduction assay (Holmgren, 1979), with
both the rate of aggregation and the lag time serving as kinetic
parameters (Martinez-Galisteo et al., 1993). For standardizing the
method, we assayed recombinant PDIA1 and PDIA3 and its sensi-
tivity was found sufficient formeasuring the activity of both PDIs,
down to a concentration of 10 nM. We, thus, attempted to apply
the insulin method for assessing the reductase activity of NusA-
Nox2(357–570), up to a concentration of 5μM, but no activity
could be detected.
We next turned to using a higher sensitivity assay, in which the
DTT-dependent disulfide reductase activity is measured by the
relief of fluorescent self quenching of the PDI pseudo-substrate
DE-GSSG, as described by Raturi and Mutus (2007). As apparent
in Figure 6A, NusA-Nox(357–570), at a concentration of 2μM,
exhibited PDI activity in marked excess over that measured with
DTT alone. The reductase activity showed clear dose dependency
(Figure 6B). Since the only catalytic motif present in Nox2 that
resembles the canonical motif of PDI (CGHC) is the CGC triad,
we looked for a correlation between the presence of the CGC
triad and activity. Such correlation was indeed found, as shown by
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the facts that NusA-Nox2(372–570), which lacks the CGC triad,
as well as NusA-Nox2(357–570) in which C369 and C371 were
mutated to arginine, exhibited an almost complete loss of PDI
activity (Figure 6C). Further proof for the PDI activity expressed
by NusA-Nox2 is shown by the fact that the PDI inhibitor, PAO
(Gallina et al., 2002) abolished the DTT-dependent disulfide
FIGURE 4 | Immunoblot of NusA-Nox2 fusion protein truncations using
anti Nox2 monoclonal antibodies 54.1 and NL7. (A) The figure illustrates
the fact that antibody 54.1 (its epitope represented by Nox2 residues
381–390) recognizes Nox2 truncations 357–570 and 372–570, and reacts
weakly with truncation 387–570. (B) Antibody NL7 (its epitope represented
by Nox2 residues 498–506) recognizes all truncations, from 357–570 to
462–570.
reductase activity at a concentration of 50μM (Figure 6D).
DTT could not be replaced by NADPH in the DE-GSSG reduc-
tion assay, when tested up to a concentration of 125μM.
No PDI activity was exhibited by the isolated Nox2 peptides
24(357–371) and 28(369–383), which contain the CGC triad,
when assayed by DE-GSSG reduction over a wide concentration
range.
In order to place Nus-Nox2 in the context of canoni-
cal PDIs, we performed dose-response reductase assays with
NusA-Nox2(357–570) in comparison to recombinant PDIA1 and
PDIA3. The concentration ranges for each protein were chosen
to assure a linear increase in fluorescence within a sufficiently
long time interval to allow reliable Vmax calculations. As seen in
Figure 7A, the activity of NusA-Nox2(357–570) (1–4μM) best
fitted a one site binding hyperbola. The NusA-Nox2(357–570)
C369R, C371R mutant was found to lack reductase activity at
concentrations of 1–4μM and, thus, no dose-response curve
could be fitted (Figure 7B). The activities of both PDIA1 (10–
80 nM) and PDIA3 (1.25–10 nM) generated linear regression
curves (Figures 7C,D). By using extrapolation of Vmax values
obtained with a concentration of 10 nM PDIA1 (37,303 ± 1279)
and 10 nM PDIA3 (1,206,911 ± 81,022) to the Vmax measured
with 1μM NusA-Nox2(357–570) (49,164 ± 2271), we calculated
that PDIA1 was about 75 times and PDIA3, 2400 times more
active than NusA-Nox2(357–570). It is of possible interest that,
using this assay, the reductase activity of PDIA3 was about 30
times higher than that of PDIA1.
Nox2 AND PDIA3 SHARE SMALL REGIONS OF SEQUENCE HOMOLOGY
In the course of the generation of a mouse monoclonal anti-
Nox2 antibody (54.1), it was found that the antibody reacted
with a protein known as GRp58 or ERp57, which is identical
to the PDIA3 member of the PDI family (Baniulis et al., 2005).
The authors noted that the cross-reaction was explained by Nox2
and PDIA3 sharing a five-residues motif (AVDGP, in the DHR of
FIGURE 5 | p67phox (1–526) and p67phox (1–212) bind to
NusA-Nox2(328–570) and NusA-Nox2(357–570) but not to shorter
Nox2 truncations. Binding of NusA-Nox2 fusion proteins and NusA,
as a control, in the fluid phase, to surface-bound p67phox (1–526) (A)
and p67phox (1–212) (B) was measured as described in the Materials
and Methods Section. All proteins were purified by gel filtration on
Superdex 200 and the homodimer-containing fractions were used in
the binding studies. The results represent one characteristic
experiment. The binding of p67phox to NusA-Nox2(328–570) and
NusA-Nox2(357–570) and the lack of binding to the five other
truncations, which did not exceed the binding to NusA, was a
constant feature of all experiments.
www.frontiersin.org February 2015 | Volume 3 | Article 3 | 9
Bechor et al. Nox2 acts as a PDIA3
FIGURE 6 | PDI reductase activity of NusA-Nox2(357–570). (A)
Recombinant NusA-Nox2(357–570) (2μM) was assayed for disulfide
reductase activity on dieosin glutathione disulfide (DE-GSSG), in the
presence of DTT, as described by Raturi and Mutus (2007) and detailed in the
Materials and Methods Section. Briefly, the reaction mixtures contained
800 nM DE-GSSG and 12.5μM DTT and the kinetics of the increase in
fluorescence were followed for 30min, using an excitation wavelength of
519 nm and an emission wavelength of 545 nm. Results are expressed as
Vmax (milli relative fluorescence units per min). (B) The dose dependence of
the PDI reductase activity of NusA-Nox2(357–570) was assayed on DE-GSSG
in the presence of DTT, as described in (A). The concentration of
NusA-Nox2(357–570) was varied from 1 to 4μM. The results of one
characteristic experiment are illustrated. (C) The absence of the
369CysGlyCys371 triad in NusA-Nox2(372–570) or mutating Cys 369 and Cys
371 to Arg in NusA-Nox2(357–570) eliminates PDI reductase activity.
NusA-Nox2(357–570), NusA-Nox2(372–570), and NusA-Nox2(357–570)
C369R, C371R (all, at a concentration of 2μM) were assayed for disulfide
reductase activity on DE-GSSG in the presence of DTT, as described in (A).
The results of one characteristic experiment are illustrated. (D) The PDI
inhibitor phenylarsine oxide (PAO) interferes with the PDI activity of
NusA-Nox2(357–570). Recombinant NusA-Nox2(357–570) (2μM) was
assayed for disulfide reductase activity on DE-GSSG in the presence of DTT,
in the absence and presence of 50μM PAO, as described in (A). The results
of one characteristic experiment are illustrated.
Nox2, and AYDGP, in PDIA3).We noticed that yet another mouse
monoclonal antibody to Nox2 (NL7) reacted with an epitope in
the DHR of Nox2 (KDVITG) which shares four residues with
sequence KDLIQG, in PDIA3. Finally, yet another minor, three-
residue identity between the DHR of Nox2 and PDIA3 (IVG),
was noticed (for all similarities, see Figure 8). The above Nox2
sequences exhibit no similarity with PDIA1.
The residues in the Nox2 sequence AVDGP shared with PDIA3
are also present in Nox3; the shared residues in Nox2 sequence
KDVITG are also present in Nox5, and shared residues IVG are
also present in Nox4. However, as noted in the Introduction, the
CGC triad is specific for Nox2. The AYDGP sequence in PDIA3 is
located in the catalytic domain a, C-terminal to the CGHCmotif;
and the IVG and KDLIQG sequences are located in domains b and
b′, respectively (Coe and Michalak, 2010; Kozlov et al., 2010).
IMMUNOBLOT ANALYSIS CONFIRMS Nox2/PDIA3 SEQUENCE
SIMILARITIES
We subjected preparations of NusA-Nox2(357–570) and
(372–570), NusA, recombinant PDI3 and PDIA1, and
macrophage membranes to immunoblotting with the two
anti-Nox2 antibodies 54.1 and NL7. As apparent in Figures 9A,B,
anti-Nox2 antibodies 54.1 and NL7 reacted with PDIA3 but
not with PDIA1. The reactivity of antibody 54.1 with PDIA3
was more pronounced than that of antibody NL7. As expected,
and as shown in Figure 4, both antibodies reacted strongly with
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FIGURE 7 | PDI reductase activities of NusA-Nox2(357–570) compared to
those of the NusA-Nox2(357-570) C369R, C371R mutant and to PDIA1
and PDIA3. (A) PDI reductase activity of recombinant NusA-Nox2(357–570)
was assayed in a concentration range of 1–4μM and plotted as non-linear
regression (one site binding equation). (B) PDI reductase activity of
recombinant NusA-Nox2(357–570) C369R, C371R mutant was assayed in a
concentration range of 1–4μM and plotted as a cubic spline curve. (C) PDI
reductase activity of recombinant PDIA1 was assayed in a concentration
range of 10–80 nM and plotted as linear regression. (D) PDI reductase activity
of recombinant PDIA3 was assayed in a concentration range of 1–10 nM and
plotted as linear regression. The assays were performed as described by
Raturi and Mutus (2007) and detailed in the Materials and Methods Section.
Results represent means ± SEM of 9 (NusA-Nox2(357–570), 4
(NusA-Npx2(357–570) C369R, C371R), 4 (PDIA1), and 3 (PDIA3) experiments.
NusA-Nox2(357–570) and (372–570) and detected a broader
and more diffuse band of about 54–58 kDa in macrophage
membranes, corresponding to the characteristics of guinea pig
Nox2 (Knoller et al., 1991). A polyclonal goat anti-Nox2 antibody
(C-15), raised against a peptide in the C-terminal region of Nox2,
which reacted with NusA-Nox2(357-570), did not react with
PDIA3 (result not shown, see Table 1). We suggest that the ability
of the two anti-Nox2 antibodies to react with PDIA3 is due to the
similarity of the Nox2 epitopes recognized by antibodies 54.1 and
NL7 with sequences AYDGP and KDLIQG in PDIA3, respectively
(see Figure 8).
In a reciprocal series of experiments, we found that the poly-
clonal anti-PDIA3 antibody H-220 reacts strongly with NusA-
Nox2(357–570) but not with Nusa-Nox2(372–570) and NusA
(Figure 10A). Its specificity is proven by its ability to recognize
recombinant PDIA3 but not PDIA1. The antibody does not seem
to recognize Nox2 in macrophage membranes in spite of the
high level of homology of human and guinea pig Nox2. It, how-
ever, detects a sharp band in the macrophage membrane, of a
size somewhat smaller than recombinant PDIA3 (see Discussion
of this finding in the paragraph below). In contrast to anti-
PDIA3, polyclonal anti-PDIA1 antibody does not react with
NusA-Nox2(357–570) (Figure 10B). Its specificity is shown by
it recognizing recombinant PDIA1, though there is some cross-
reaction with PDIA3. Anti-PDIA1 also recognizes an antigen
in the macrophage membrane (double band), possibly PDIA1.
These findings are best explained by the likelihood that polyclonal
anti-PDIA3 antibody H-220, raised against residues 108–207 of
PDIA3, comprises antibodies against sequence AYDGP (residues
114–118), similar to sequence AVDGP (residues 386–390) in
Nox2, and, possibly IVG (residues 156–158), identical to sequence
IVG (residues 357–359) in Nox2. We have no explanation for
the lack of reaction of anti-PDIA3 H-220 with truncation NusA-
Nox2(372–570), unless the participation of epitope IVG [absent
in NusA-Nox2(372–570)] is required.
We next investigated the identity of the sharp band detected
by anti-PDIA3 H-220 in macrophage membranes. For this pur-
pose, we immunoblotted four individual batches of macrophage
membranes withmonoclonal anti-Nox2 antibody 54.1, in parallel
with four polyclonal anti-PDIA3 antibodies (H-220, HPA003230,
NBP-84797, and ABE1032; the characteristics of the antibod-
ies are described in Materials and Methods). With the excep-
tion of H-220, none of the anti-PDIA3 antibodies recognized
recombinant NusA-Nox2(357–570) and none of the antibod-
ies recognized Nox2 in macrophage membranes. However, all
four anti-PDIA3 antibodies detected a protein of about 58 kDa
in all batches of macrophage membranes in the shape of a
sharply defined narrow band, indicating that PDIA3 is present in
the membrane (see Figure 11, illustrating results obtained with
anti-Nox2 antibody 54.1 and anti-PDIA3 antibody HPA003230).
Monoclonal anti-Nox2 antibody 54.1 reacted with Nox2 in
membranes (a diffuse band) but also with what appears to
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FIGURE 8 | Amino acid sequence similarities between the
dehydrogenase region of Nox2 and PDIA3. The figure illustrates three
small regions (3–6 residues) exhibiting partial sequence identities
between Nox2 and PDIA3. The representation of the motifs in
non-phagocytic Noxes (Noxes 1, 3, 4, and 5) is also shown. Monoclonal
anti-Nox2 antibody 54.1 recognizes Nox2 residues 381KLPKIAVDGP390 and
might recognize PDIA3 residues 114AYDGP118 (see Figure 9A).
Monoclonal anti-Nox2 antibody NL7 recognizes Nox2 residues
498EKDVITGLK506 and might recognize PDIA3 residues 252KDLIQG257
(see Figure 9B). Polyclonal anti-PDIA3 antibody H-220 was raised against
PDIA3 residues 108–207 and could potentially recognize PDIA3
114AYDGP118 and 156IVG158 and Nox2 residues 386AVDGP390 and
357IVG359, respectively (see Figure 10A). The regions of Nox2/PDIA3
homology do not exist in the sequence of PDIA1, in good agreement
with the fact that the two anti-Nox2 antibodies do not recognize PDIA1
(see Figures 9A,B) and a polyclonal anti-PDIA1 antibody does not
recognize Nox2 (see Figure 10B). Identical residues in different proteins
are in red font; the CGC triad in Nox2 is in orange font.
be PDIA3 present in the membrane, appearing as a narrow
band on the background of the more diffuse Nox2, corre-
sponding in size to the band detected by anti-PDIA3 antibody
HPA003230. The presence of PDIA3 in macrophage membranes
might offer the explanation for the inability of anti-PDIA3 anti-
body H-220 to recognize Nox2 in the membrane; this could be
due to competition by membrane PDIA3, to which the anti-
body is likely to bind with higher affinity. All results obtained
by immunoblotting are summarized in Table 1. The presence
of PDIA3 (and PDIA1) in macrophage membranes, although
expected in light of the ubiquity of PDIs even outside the endo-
plasmic reticulum (Turano et al., 2002), poses a methodologi-
cal challenge when investigating the PDI-like function of Nox2
and emphasizes the advantage of working with recombinant
Nox2.
MUTATING CYSTEINES IN p67phox (1–212) TO SERINE PREVENTS
BINDING TO A Nox2 DHR PEPTIDE CONTAINING THE CGC TRIAD
The data presented so far suggest that the CGC triad in the
DHR of Nox2 serves as a pseudo-PDI catalytic motif lead-
ing to the binding of p67phox to Nox2 via a thiol-disulfide
exchange reaction. Since such a reaction must involve cysteine(s)
in p67phox and since oxidation or alkylation of cysteines in
p67phox abolished binding to CGC-containing Nox2 peptides (see
Figure 2), we reasoned that mutating the cysteines in p67phox
should prevent binding to these peptides and also affect oxidase
activation.
Full-length p67phox contains nine cysteines and p67phox(1–
212) contains four. Based on the knowledge that p67phox(1–212)
binds to NusA-Nox2 and to CGC-containing Nox2 peptides and
supports oxidase activation in vitro with an efficiency identical
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FIGURE 9 | Two monoclonal anti-Nox2 antibodies react with PDIA3
but not with PDIA1 by immunoblotting. (A) Monoclonal anti-Nox2
antibody 54.1 (epitope, residues 381–390) reacts with recombinant
NusA-Nox2(357–570) and NusA-Nox2(372–570) but not with NusA. It
reacts strongly with recombinant PDIA3 but not with recombinant PDIA1.
It recognizes a protein of about 54–58 kDa (diffuse band) in the guinea pig
macrophage membrane, corresponding to Nox2 (Knoller et al., 1991). (B)
Monoclonal anti-Nox2 antibody NL7 (epitope, residues 498–506) reacts
with recombinant NusA-Nox2(357–570) and NusA-Nox2(372–570) but not
with NusA. It reacts moderately with recombinant PDIA3 but not with
recombinant PDIA1. It recognizes a protein of about 54–58 kDa (diffuse
band) in the guinea pig macrophage membrane, corresponding to Nox2.
Nox2(357–570) numbered 1, 2, and 3 represent three batches of
NusA-Nox2(357–570).
Table 1 | Cross-reactivity of some anti-Nox2 antibodies with PDIA3 and of some anti-PDIA3 antibodies with Nox2.
Protein Antibodies
Anti-Nox2 Anti-Nox2 Anti-Nox2 Anti-PDIA3 Anti-PDIA3 Anti-PDIA3 Anti-PDIA3 Anti-PDIA1
54.1 NL7 C-15 H-220 HPA003230 NBP1-84797 ABE1032 H-160
Mouse Mouse Goat Rabbit Rabbit Rabbit Rabbit Rabbit
monoclonal monoclonal polyclonal Polyclonal Polyclonal polyclonal polyclonal polyclonal
NusA-Nox2
(357–570)
+ + + + − − − −
NusA-Nox2
(372–570)
+ + NDa − − NDa − NDa
PDIA3
(recombinant)




+ + NDa + + + + +c
PDIA1
(recombinant)
− − − − − − +/−b +
a ND, not determined.
b Weak reaction in comparison to that with the specific antigen.
c PDIA1 was detected; detection of PDIA3 could not be established with certainty because of similarity in size with PDIA1.
to that of the full-length protein, we mutated the four cysteines
present in p67phox(1–212) (cysteines 40, 45, 121, and 165) to ser-
ines. The wild-type protein and the mutated protein were found
by gel filtration to have a native molecular mass of 28.4 and
27.4 kDa, respectively, in good agreement with the theoretical
value of 25.5 kDa. The only difference between the two proteins
was an apparent increase in the hydrophobic character of the
mutant protein (see Materials and Methods). We confirmed the
absence of cysteines in the mutant protein by comparing the
binding of the thiol probe mBBr (Kosower and Kosower, 1995)
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FIGURE 10 | A polyclonal anti-PDIA3 antibody but not a polyclonal
anti-PDIA1 antibody reacts with Nox2 by immunoblotting. (A)
Polyclonal anti-PDIA3 antibody H-220 reacts with recombinant
NusA-Nox2(357–570) but not with NusA-Nox2(372–570) and NusA. It
reacts strongly with recombinant PDIA3 but not with recombinant PDIA1.
It also recognizes a protein in the guinea pig macrophage membrane
(sharp single band). (B) Polyclonal anti-PDIA1 antibody H-160 does not
react with recombinant NusA-Nox2(357–570) and NusA-Nox2(372–570). It
reacts with recombinant PDIA1 and weakly, with recombinant PDIA3. It
also recognizes a protein in the guinea pig macrophage membrane (sharp
double band). Nox2(357–570) numbered 1, 2, and 3 represent three
batches of NusA-Nox2(357–570).
to the wild-type and mutant proteins. Wild-type protein indeed
bound mBBr, whereas the mutant protein did not (results not
shown).
The binding of wild type and mutant p67phox to Nox2 DHR
peptide 24 comprising the CGC triad, in either the dithiol or
disulfide form, was assessed by the peptide—protein binding
assay. As apparent in Figures 12A,B, the wild type protein exhib-
ited moderate binding to peptide 24 in the reduced form and
much enhanced binding to the disulfide form. The mutant pro-
tein lacked binding ability to both forms of the peptide. The total
absence of binding of the mutant protein to the disulfide form of
peptide 24 is especially noteworthy.
MUTATING CYSTEINES IN p67phox (1–212) TO SERINE INTERFERES
WITH NADPH OXIDASE ACTIVATION
We next assayed wild-type and mutant p67phox(1–212) for their
ability to support oxidase activation in the cell-free system. We
compared the two proteins in the amphiphile- and p47phox-
dependent and in the amphiphile- and p47phox-independent sys-
tems. As seen in Figures 13A,B, there was a two-fold increase in
the EC50 of the mutant p67phox in both assays, indicating that that
the mutant protein has a significantly impaired ability to sup-
port oxidase activation. In accordance with our hypothesis, the
mutant protein did not loose its activity completely, as expected
from an effect of the stability of the assembled oxidase com-
plex, as opposed to an effect on the primary interaction, which
would result in a total loss of activity. Cysteine mutagenesis was
applied in the past to p47phox and shown to result in a paradox-
ical increase in the ability to support oxidase activation by an
unknown mechanism (Babior, 2002).
THE MAJORITY OF PDI INHIBITORS DO NOT AFFECT NADPH OXIDASE
ACTIVATION IN VITRO
It has been reported that two PDI inhibitors, bacitracin and
scrambled RNAs, inhibit oxidase activation in an amphiphile-
dependent cell-free system, consisting of neutrophil membranes
and recombinant cytosolic components (Paes et al., 2011). As
referred to in the Introduction, PAO and gliotoxin, two com-
pounds binding to vicinal cysteines and, most likely, acting on
C369 and C371 in Nox2, were reported to inhibit oxidase activa-
tion. PAO is considered to act as a PDI inhibitor (Gallina et al.,
2002) and direct evidence for this was presented by Raturi et al.
(2005) and also appears in Figure 6D. Direct proof for gliotoxin
acting as a PDI inhibitor is lacking.
We, thus, engaged in a systematic investigation of the effect of
a number of compounds, reported to act as PDI inhibitors on a
variety of targets and in various situations, on cell-free oxidase
activation. The amphiphile- and p47phox-independent assay was
used, in order to reduce the number of potential targets for the
inhibitors. Since p47phox was described to associate with exoge-
nous PDI (Paes et al., 2011), we preferred to work in a system
free of p47phox. In addition to PAO and gliotoxin, the following
PDI inhibitors were tested: bacitracin (Dickerhof et al., 2011),
scrambled RNAse (Essex and Li, 1999), 16F16 (Hoffstrom et al.,
2010), rutin (Jasuja et al., 2012), and PACMA 31 (Xu et al., 2012).
In all assays, the potential inhibitor was preincubated with the
membrane component before the induction of oxidase complex
assembly. As shown in Figure 14, significant inhibition of oxidase
activation was caused only by PAO (Figure 14A), in accordance
with earlier work (Le Cabec and Maridonneau-Parini, 1995;
Doussiere et al., 1998). However, in preliminary experiments
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FIGURE 11 | Detection of PDIA3 in macrophage membranes by both
anti-Nox2 and anti-PDIA3 antibodies. Monoclonal anti-Nox2 antibody
54.1, which recognizes recombinant PDIA3 (see Figure 9A), is shown
to detect in macrophage membranes an antigen most likely to be
PDIA3. This appears in four distinct membrane batches as a sharply
defined band on the background of the more diffuse Nox2; the overlap
is caused by the almost identical size of guinea pig Nox2 and PDIA3.
A polyclonal anti-PDIA3 antibody (HPA003230), found not to cross-react
with Nox2 (see Table 1), detects PDIA3 in macrophage membranes.
The position and character of the bands detected by anti-PDIA3
strengthens the proposal that the sharp band detected by anti-Nox2
represents PDIA3.
(results not shown), we found that PAO also inhibited oxidase
activation supported by p67phox with cysteines mutated to serines,
a finding which raises questions about its mechanism of action. It
was, indeed, reported that PAO also had an effect on the heme of
Nox2 (Doussiere et al., 1999). Gliotoxin was found to be a poor
inhibitor, when tested up to a concentration of 200μM, and gen-
erated an atypical dose-response curve, a result which differed
from the marked inhibitory effect reported in the past (Nishida
et al., 2005). Bacitracin was also found to be a poor inhibitor, with
an IC50of 602μM and a maximal inhibition not exceeding 60%,
and scrambled RNAse was ineffective, up to a concentration of
14.6μM. Lack of an inhibitory effect was also found for 16F16
(up to 14.6μM), rutin (up to 400μM), and PACMA 31 (up to
500μM).
These results do not counter our hypothesis that the DHR
of Nox2 functions as a PDI. Nox2 possesses only one copy of
a catalytic site resembling CGHC and lacks the equivalent of
a substrate binding domain (b′). Bacitracin is unlikely to be
an effective inhibitor, first because its target in PDI is the b′
domain and its linker to domain a′, both absent in Nox2, and
second because commercial bacitracin consists predominantly of
bacitracin A, of low inhibitory potency (Dickerhof et al., 2011).
Isomerization by PDI also requires the b′ domain (Ellgaard and
Ruddock, 2005) and, thus, an interaction between Nox2 and
scrambled RNAse is unlikely. The mechanism of action of 16F16
and rutin are not fully understood but it is of interest that rutin
was found to lack an inhibitory effect on PDIA3 (Jasuja et al.,
2012). The lack of effect of PACMA 31 is also expected, consid-
ering the exquisite specificity of the compound for PDIA1 and,
more specifically for cysteines in the catalytic motif in domain a′,
in conjunction with additional non-cysteine residues (Xu et al.,
2012).
DISCUSSION
Our results support a model of NADPH oxidase assembly and
consequent activation in which the cytosolic component p67phox,
most directly responsible for activation, establishes a disulfide
bond with a cysteine belonging to the 369CysGlyCys371 triad in the
DHR of Nox2. This interaction serves as a stabilizer of the oxidase
complex and is, most likely, secondary to the primary binding
of p67phox to Nox2, which involves specific binding sites on both
components.
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FIGURE 12 | Mutating all four cysteines in p67phox (1–212) eliminates
its ability to bind to Nox2 peptide 24. Binding of wild type
p67phox (1–212) and p67phox in which 40Cys, 45Cys, 121Cys, and 165Cys
were mutated to Ser, in solution, to surface-attached Nox2 peptide 24
(357–371), with an N-terminal biotin tag, in the dithiol form (labeled
24N CGC), and with an intramolecular disulfide bond between cysteines
C369 and C371 (labeled 24N CGC S-S), was assessed. The
methodology is described in the Materials and Methods Section. (A)
Binding of the mutant protein to both forms of the peptide is
markedly reduced. Results represent means ± SEM of 3 experiments.
(B) End point view of the wells of a 10min kinetic experiment (A).
The depth of the blue-green color, representing oxidized TMB, is
proportional with the binding of wild type and mutant p67phox to the
peptides. Results are those of a single representative experiment.
Earlier findings that were suggestive of such amechanismwere:
(a) p67phox binds to Nox2 peptides sharing the CGC triad at
either the C- or N-termini; (b) p67phox does not bind to pep-
tides when either C369 or C371 are replaced by arginine or serine;
(c) The CGC triad is present only in Nox2, the most potent gen-
erator of superoxide among all members of the Nox family, and
the one most dependent on regulation by cytosolic components,
and (d) The introduction of a disulfide bond between C369 and
C371 in Nox2 peptides greatly enhances binding of p67phox and
its reduction to the dithiol form abolishes the binding.
Work by other groups also supports our hypothesis. Thus,
patients with a C369 to R mutation in Nox2 suffer from the
X91+ form of CGD, with normal expression of Nox2 but
impaired translocation of cytosolic components (Leusen et al.,
2000; Debeurme et al., 2010). It was also reported that exposure
of phagocyte membranes to H2O2 or of p67phox to irradiation
generating oxygen radicals, with a presumed effect on cysteines,
inhibits oxidase assembly but was without effect on the assembled
complex (Ostuni et al., 2010).
An important prerequisite for binding of p67phox to Nox2
was the presence of a disulfide bond between cysteines 369 and
371. The characteristics of this bond are critical for binding,
as shown by the requirement for cysteines to be separated by
one non-cysteine residue and for their presence in the same
molecule. Contrary to expectations, replacing the native CGC
triad in the Nox2 peptides with the PDI (CGHC) or thioredoxin
(CGPC) catalytic motifs did not result in enhanced binding. The
requirement for a disulfide bond in Nox2 peptides for binding
of p67phox was one of the first indicators for a PDI-like func-
tion of Nox2, in accordance with the thiol—disulfide exchange
reactions catalyzed by canonical PDIs (Ellgaard and Ruddock,
2005; Appenzeller-Herzog and Ellgaard, 2008). This raises the
issue of the physiological mechanism to take place in the intact
phagocyte responsible for the generation of the disulfide bond,
when taking into account the fact that the cytosolic environ-
ment of the DHR of Nox2 is a reducing one. Also, such bond
has to return to the dithiol state in order to assure the reversibil-
ity of the Nox2—p67phox link. The stability of this link is a yet
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FIGURE 13 | Mutating all four cysteines in p67phox (1–212) impairs its
ability to support NADPH oxidase activation in a cell-free system.
Wild-type p67phox (1–212) and p67phox in which 40Cys, 45Cys, 121Cys, and
165Cys were mutated to Ser, were assayed for the ability to support
NADPH oxidase activation in a cell-free system. Two forms of assay were
used. (A) The first (amphiphile- and p47phox -dependent) consisted of
macrophage membrane liposomes (5 nM cytochrome b558 heme), equal
concentrations of p67phox (wild-type or mutant), p47phox , and Rac1 Q61L,
varying from 10 to 200 nM, and LiDS (120μM). Activation proceeded for
90 s, followed by addition of 240μM NADPH, to initiate O·−2 production. (B)
The second (amphiphile- and p47phox -independent) consisted of
macrophage membrane liposomes (5 nM cytochrome b558 heme) and
equal concentrations of p67phox (wild-type or mutant) and prenylated Rac1
Q61L, varying from 50 to 600 nM. Activation proceeded for 5min, followed
by addition of 240μM NADPH, to initiate O·−2 production.
unsolved issue and depends on the conditions leading to the
activation of the oxidase (van Bruggen et al., 2004; Tlili et al.,
2012).
We can envisage several mechanisms for the oxidation of cys-
teines in Nox2. The oxidizing agent might be H2O2 derived by
dismutation of O·−2 generated by the oxidase itself, leaking into
the cytosolic milieu of the DHR of Nox2 (Enyedi et al., 2013).
Another possibility is the intercalation of the CGC triad into the
redox cascade of Nox2, from NADPH, via FAD/FADH2, to heme
(Cross and Segal, 2004). An additional hypothetical mechanism is
oxidation by an exogenous PDI in the oxidized form or by another
thiol oxidase. Paes et al. (2011) indeed showed that addition
of oxidized PDI enhanced oxidase activation in a cell-free
system.
The involvement of a PDI in the assembly of the NADPH oxi-
dase was championed by the group of F. Laurindo. They provided
extensive experimental evidence for a role of a PDI in the regu-
lation of NADPH oxidase activity in vascular smooth muscle and
endothelial cells, suggesting a role in the stabilization of oxidase
subunits assembly (Laurindo et al., 2008). A more specific role in
the activation of phagocyte oxidase activation was also described,
expressed in the ability of exogenous oxidized PDI to enhance
and of reduced PDI to diminish oxidase activation in vitro (Paes
et al., 2011). A peptide comprising the CGHC PDI catalytic motif
inhibited oxidase activation and PDI–p47phox and PDI–p22phox
associations were demonstrated (Santos et al., 2009; Paes et al.,
2011).
We propose that, independently of the regulation of Nox2-
dependent oxidase activity by an exogenous PDI, the DHR of
Nox2 itself functions as an intrinsic PDI. The evidence for this
is as follows:
1. By assessing the binding of p67phox to seven NusA-Nox2 fusion
proteins, serially truncated at the N-terminus of the Nox2moi-
ety, we found that binding required the presence of the CGC
triad.
2. Fusion protein NusA-Nox2(357–570), which comprises
the CGC triad, expressed dose-dependent PDI reductase
activity.
3. Truncation of the Nox2 moiety in the NusA-Nox2 fusion pro-
tein C-terminal to the CGC triad or mutating C369 and C371
to R, resulted in the loss of PDI activity.
4. The PDI activity of NusA-Nox2 was suppressed by PAO.
5. A comparison of the sequence of the DHR of human Nox2
with several PDIs, revealed three small regions of homology
with PDIA3.
6. Two monoclonal anti-Nox2 antibodies, with epitopes corre-
sponding to two regions of Nox2/PDIA3 similarity, reacted
with PDIA3 but not with PDIA1.
7. One polyclonal anti-PDIA3 antibody (but not an anti-PDIA1
antibody) reacted strongly with recombinant NusA-Nox2.
8. p67phox(1–212) in which all four cysteines were mutated to
serines lost the ability to bind to a Nox2 peptide comprising
the CGC triad and its capacity to activate the oxidase was
impaired.
PDIA3 (also known as ERp57 or GRp58) is a 505-residues long
protein, with a molecular mass of 56.78 kDa, found in the endo-
plasmic reticulum but also on the cell surface, plasma membrane,
nucleus, cytosol, and in the secreted form (Frickel et al., 2004; Coe
and Michalak, 2010). Its structure is similar to other PDIs (33%
overall identity), with two catalytic domains (a and a′) compris-
ing the CGHC motif and disulfide reduction potentials of −167
and−156mV, respectively. It catalyzes disulfide reduction, dithiol
oxidation, and disulfide isomerization. Its reductase activity was
reported to be 20 times less efficient than that of PDIA1, using
the insulin assay (Frickel et al., 2004); this is in disagreement with
our finding, based on the DE-GSSG reduction assay, of a 30-fold
higher activity of PDIA3 compared to PDIA1. PDIA3 promotes
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FIGURE 14 | Effect of PDI inhibitors on NADPH oxidase activation in a
cell-free system. Selected PDI inhibitors were tested for their ability to
interfere with NADPH oxidase activation in an amphiphile- and
p47phox -independent system. The reaction mixtures contained macrophage
membrane liposomes (5 nM cytochrome b558 heme), p67phox (1–212)
(300 nM), and prenylated Rac1 Q61L (300 nM). The membrane liposomes
were preincubated with the PDI inhibitors for 5min, followed by the addition
of p67phox and Rac1, incubation for 5min in the absence of an amphiphilic
activator, and the addition of 240μM NADPH, to initiate O·−2 production. The
effect of the following inhibitors is described in the figure: (A) phenylarsine
oxide (1.56–200μM); (B) bacitracin (62.5–2000μM); (C) gliotoxin
(1.56–200μM), and (D) scrambled RNAse (0.114–14.6μM). Results represent
means ± SEM of 3 experiments, for each of the inhibitors tested. IC50 values
are indicated for phenylarsine oxide and bacitracin but could not be
determined for gliotoxin and scrambled RNAse, due to the absence of curves
amenable to kinetic analysis.
folding of glycoproteins in the endoplasmic reticulum and is a
key component of the MHC-I peptide loading complex (Purcell
and Elliot, 2008). A newly discovered role is that of a GDP disso-
ciation inhibitor for the Ras family small GTPase Ra1A (Brymora
et al., 2012).
The PDI reductase activity of NusA-Nox2(357–570) is much
lower than that of recombinant PDIA1 and PDIA3, when com-
pared by the DE-GSSG reduction assay. The reason for this might
be the difference between the catalytic motifs (CGC, in Nox2,
and CGHC, in most PDIs), the presence of two catalytic motifs
in most PDIs, or the lesser affinity of Nox2 for the DE-GSSG
substrate. Our results do not allow the allocation of functional
roles to regions of homology between Nox2 and PDIA3. An evo-
lutionary link between the two proteins is also unlikely. The most
conservative interpretation is to look upon Nox2 as a relative of
the large family of thiol-disulfide oxidoreductases, characterized
by a CXXC motif (reviewed in Sevier and Kaiser, 2002).
In conclusion, we have described a rather unique situation,
in which one protein (Nox2) mimics the enzymatic function
of a seemingly unrelated protein (PDIA3), with which it shares
a similar catalytic motif and minor sequence homology. We
plan to expand this study by identifying the individual cys-
teines in p67phox involved in binding to Nox2 and by designing
NADPH oxidase inhibitors focused on the Nox2 CGC - p67phox
interaction.
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